Mr. Caffoe is a founding member of the family of ImQuest Companies which began in 2004 and he became the interim CEO, Chairman, and President of ImQuest Life Sciences early in 2008.He has been a very important part of the company’s reorganization that began late in 2007 and has implemented new operational and development plans that will allow ImQuest to raise the additional funds needed to move the company’s products to human clinical trials.From 1979 until 1993 Mr. Caffoe owned and operated his own golf facilities and then in 1994 he became a Life Member of the Professional Golfers Association of America.Mr. Caffoe is currently a licensed Insurance Broker in the State of Indiana. He has also been involved in the real estate industry as an investor and developer and has owned and operated a number of different businesses during his lifetime.
Dr. Robert W. Buckheit, Jr., Ph.D.
Founder, President, and Chief Scientific Officer
Dr. Buckheit is a well-respected and internationally recognized virologist with over 20 years of experience in the research and development of therapies for human cancer and AIDS. His experiences include AIDS drug development, immunology, retrovirology, molecular biology and antiviral and anti-cancer assay development. Educated and trained at Duke University and The University of North Carolina at Chapel Hill, Dr. Buckheit has focused on the development of anti-infective therapies to prevent the transmission and spread of infectious disease, including evaluation of efficacy and toxicity, range and mechanism of anti-infective action, anti-infective resistance, anti-infective combination therapy and animal model development. Dr. Buckheit is well-versed in the use of both cell based and molecular/biochemical assays as components of drug development algorithms and has participated in the development of dozens of compounds which have progressed to IND submission and human clinical testing. Dr. Buckheit has developed and managed anti-infective and anti-cancer drug development programs in the CRO sector for the bulk of his career, including the development of drugs for the therapy of HIV, hepatitis B & C, herpes simplex virus, respiratory and enteric viruses, bacterial and fungal pathogens and bio-defense related organisms. At ImQuest, Dr. Buckheit has been awarded over $12 million in research grants from the National Institutes of Health, including Phase 1 and 2 Small Business Innovation Awards. Dr. Buckheit sits on the Editorial Boards of the journals Antiviral Research and Expert Opinion on Investigational Drugs and is an ad hoc reviewer for the Journal of Virology and Antimicrobial Agents and Chemotherapy as well as numerous other journals. Dr. Buckheit is also an active member of the International Society for Antiviral Research and is the Program Chair for the annual conference of the Society (ICAR). Dr. Buckheit has authored over 150 papers in the peer reviewed literature and regularly presents laboratory data at a variety of international scientific meetings.
Dr. Daniel A. Biehl
Daniel Biehl, MD, a northwestern Michigan native, attended
MichiganTechUniversity
and Wayne State University School of Medicine. After completing a residency in General Pediatrics at
MichiganStateUniversity
, he concluded his formal training with a fellowship in Neonatal-Perinatal Medicine at the
University
of
Louisville
. During his fellowship, Dr. Biehl’s research was in clinical applications of ECMO. Dr. Biehl moved to
Fort Wayne, Indiana
, in 1998, after serving in the Air Force where he was the director of ECMO for Wilford Hall for 3 years. Dr. Biehl is the Medical Director of the Neonatal Intensive Care Units at both
LutheranHospital
and
St. JosephHospital
in Fort Wayne, Indiana and he holds board seats at both
MonroeHospital
in Bloomington, Indiana and the Children’s Hope House of Fort Wayne. Outside of medicine, his interests include training for a number of different types of marathons in which he participates. He’s striving to compete in at least one marathon in all 50 states and to date has competed in 35 different states.
Mr. Dan Williams, JD., LLM
Chief Financial Officer
Mr. Williams has over 20 years of legal and tax consulting experience, serving in a number of capacities in corporations of all sizes including most recently a fortune 500 company. He possesses, in addition to his undergraduate degree, a Master of Laws in International Business, a Master of Laws in Taxation with a specialty in Corporate Taxation and the Doctor of Jurisprudence.Over the past 20 years, Mr. Williams has been involved in a myriad of transactions addressing all aspects of Business and Corporate legal matters as well as taxation in Domestic and International areas. In addition, Mr. Williams has advised and handled mergers and acquisitions, SEC regulatory matters, internal and exterior audits by International, Federal and State taxing authorities on small and large case. As a member of the tax management team with a fortune 500 company, Mr. Williams was involved in various functions overseeing both federal and international tax accounting and compliance issues. He has worked with various Governmental agencies in establishing compliance and structuring specialized programs for those clients.
